CD31 was significantly lower in the groups treated with anti‐EGFL7, anti‐VEGF, or a combination of both blocking antibodies as compared to control, advocating treatment‐driven inhibition of tumor vascularization (Fig 6A and B). This evidence concerns the gene EGFL7 and neoplasm.